Thirty years ago most patients with type 2 diabetes did not develop the disease until they were in their late 60’s. They often did not develop the cardiovascular or kidney problems that we are so worried about today. This was likely due to their advanced age at diagnosis and a …

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes. 

New study findings challenge the link between neuropathic pain and vitamin D levels in people with type 2 diabetes.

Could older recommendations of maintaining a blood pressure of 140/90 mmHg be misleading in younger adults with type 1 diabetes for cardiovascular risk reduction? 

Findings show statin use tied to higher HbA1c values, with longer statin use tied to greater risk for diabetes

Greater organ-absorbed doses may be modestly positively associated with risk of solid cancer death

Survival benefit not seen with ever use of metformin for pancreatic cancer-related diabetes

Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for June 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.Medtronic Recalls …

Lower values for resorption end points at month two persisted to month 12, indicating reduced turnover

Last week our intern Marian Ayad, BSPharm, PharmD candidate, University of Colorado, was talking to me about the problems that occur when there is a lower age limit on the use of a medication. She had been reviewing PI’s on various diabetes medications and constantly found that most of them …